iVascular Angiolite DES Evaluated at 5 Years in RANGO Registry

February 20, 2025—iVascular announced 5-year results from the RANGO registry evaluating the long-term safety and efficacy of the company’s Angiolite sirolimus drug-eluting stent (DES) in unselected patients in real-world practice.

According to iVascular, RANGO is a prospective, single-arm, multicenter, observational, multinational registry. The study included 654 patients enrolled at 16 academic medical centers in Spain and Portugal between June 2017 and July 2018.

As summarized in the company’s press release, the primary objective of RANGO was to evaluate 5-year target lesion failure (TLF), defined as cardiac death, myocardial infarction (MI) not clearly attributable to a nonintervention vessel, and clinically driven target lesion revascularization. Secondary objectives included target vessel failure (TVF), a patient-oriented composite endpoint, and stent thrombosis.

The company reported that the all-cause mortality rate was 13.4% at 5 years with a cardiac cause-of-death rate of 5.9%. The incidence of MI was 5.1% and stent thrombosis was 1.2%.

In the group treated only with the Angiolite DES, the TLF rate was 7.7%, the TVF rate was 8.7%, and the stent thrombosis rate was 0.9%, noted the company.

The low rates of stent thrombosis and cardiac mortality highlight the long-term safety of the device, and the low TLF rate and patient-oriented composite endpoint underscore the efficacy of improving clinical outcomes and patient quality of life, stated iVascular.

“The 5-year results of the RANGO registry are very encouraging, fully comparable to previous results of other DESs, and confirm the efficacy and safety of the Angiolite stent in a wide variety of patients,” commented Principal Investigator Armando Pérez de Prado, MD, in the company’s press release. “These findings reinforce the confidence in using this device in everyday clinical practice.”

In June 2022, iVascular announced 3-year results from the RANGO registry, which were presented by Dr. Pérez de Prado at the EuroPCR 2022 conference in Paris, France.